Annals of Oncology Advance Access originally published online on April 20, 2006
Annals of Oncology 2006 17(9):1465; doi:10.1093/annonc/mdl052
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
letters to the editor |
Promotion of neurogenesis by human stem cells in high-risk breast cancer survivals after stem-cell supported high-dose therapy
1 Department of Medical Oncology, Hacettepe University Institute of Oncology Ankara, Turkey
2 Department of Internal Medicine, Beirut Governmental University Hospital, Beirut, Lebanon
3 Department of Clinical Oncology, Hospital Maternidade De Campinas, Campinas, SP, Brazil
*(E-mail: drkadri{at}usa.net)
We read the study by Scherwath et al. [1] in which they evaluated the impact of high-dose versus standard-dose chemotherapy on the late neuropsychological outcome in high-risk breast cancer patients. Their analysis showed that after 5 years of treatment, standard-dose patients had more impaired cognitive performance than high-dose patients (13% versus 8%). Stem cells from bone marrow and other sources have been shown to repair injured tissues by differentiating into tissue-specific phenotypes [2]. Neurogenesis by neuronal stem cells and survival of newly differentiated cells can contribute to self-repair after neuronal loss [3]. Moreover, a recent study showed that human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice [4]. Taken all together, since high-dose patients were supported by autologous bone marrow stem cells, they might have enhanced neurogenesis in their brain induced by increased neurogenic stem cells through the differentiation of bone marrow stem cells in a response to chemotherapy-induced neuronal loss. This proposal might explain, in part, better neuropsychological outcome in high-dose patients compared with normal-dose patients.
 |
References |
|---|
 Top References |
|---|
1. Scherwath A, Mehnert A, Schleimer B, et al. (2006) Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 17:415–423.
2. Prockop DJ, Gregory CA, Spees JL. (2003) One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 100:Suppl 1, 11917–11923.
3. Arvidsson A, Collin T, Kirik D, et al. (2002) Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 8:963–970.[CrossRef][Web of Science][Medline]
4. Munoz JR, Stoutenger BR, Robinson AP, et al. (2005) Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci USA 102:18171–18176.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A Scherwath Reply to 'Promotion of neurogenesis by human stem cells in high-risk breast cancer survivals after stem-cell supported high-dose therapy' by K. Altundag et al. (Ann Oncol 2006; 17: 1465) Ann. Onc., September 1, 2006; 17(9): 1465 - 1466. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||